Stemchymal
Phase 2Biologic
Stemchymal is one of 24 biologic programs targeting Acute Liver Failure. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in Cerebellar Ataxia
#DrugCompanyPhaseTrials
1Fampridine
BiogenPhase 3
Rilutek
AAzurity Pharmaceuticals
Phase 2
Lithobid
SSolvay Pharmaceuticals
Phase 2
Tasigna
AAzurity Pharmaceuticals
Phase 2
Asceniv
CSL BehringPhase 1
Ivig
ArgenxPhase 2
SLS-005
SSeelos Therapeutics, Inc.
Phase 3
Stemchymal
SSteminent Biotherapeutics Inc.
Phase 2
CAD-1883
CCadent Therapeutics
Phase 2
Ampyra
MMerz Pharmaceuticals GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stemchymal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SSteminent Biotherapeutics Inc.